Consumer Staples · Specialty Cleaning, Polishing and Sanitation Preparations

CLX Clorox SEC Filings & Insider Trading Activity 2026

company
CIK 21076122 filings
S&P 500

CLX at a glance

Clorox (CLX, SEC CIK 21076) filed its latest 10-K annual report on August 7, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2025 (FY2025), Clorox (CLX) reported revenue of $7.1 billion (up 0.2% from FY2024) and net income of $810.0 million. Diluted EPS was $6.52.
  • As of September 30, 2026, 45 institutional investment managers tracked by SignalX reported holding Clorox (CLX) shares worth $4.5 billion in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Breber Pierre R on November 4, 2026 of 4,000 shares at $100.06 per share.
  • In the last 90 days, CLX insiders reported 1 open-market purchase ($400K) and 0 open-market sales ($0) on Form 4, a net purchase of $400K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$7.1B
+0.2% vs prior year
Insiders · 90 days
1 buy · 0 sells
Net +$400K
13F holders
45 funds
$4.5B · −2 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 5.07

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Management Discussion & Analysis

  • Revenue details not explicitly stated; focus on cash flows: Operating cash flow $612M in 2026 vs. $981M in 2025, decrease due to Venture Agreement and lower cash earnings
  • Operating margin or profit metrics not provided; adjusted free cash flow 13.1% of net sales in 2026 vs. 10.7% in 2025
  • Best performing segment details not disclosed; largest cash outflow from investing activities $2,301M in 2026 mainly due to GOJO acquisition
  • Financing cash flow $1,668M in 2026 vs. $(924)M in 2025 driven by higher borrowings for GOJO; Stock repurchases $254M; Dividends per share $4.96 in 2026, up from $4.88 in 2025
  • Management expects sufficient liquidity supported by positive future cash flow, strong credit ratings (S&P: A-2/BBB+), and available revolving credit lines totaling $1,964M

Business Overview

  • Core business model: Multinational manufacturer and marketer of consumer and professional products with $6.7B net sales, 9,200 employees across 25 countries (FY 2026)
  • New acquisition: April 2026 acquisition of GOJO, expanding health and hygiene segment and B2B channels, including Purell brand and dispensing systems
  • Strategic shift: Expiration of P&G joint venture in January 2026; acquired full ownership of Glad business, increasing standalone operational responsibility
  • Quantitative metric: $580 million invested in transformational technologies including new ERP system completed in Q3 FY 2026; employee count increased due to GOJO acquisition
  • Noteworthy fact: Recordable incident rate (RIR) of 0.63 in FY 2026, significantly below 2024 U.S. goods manufacturing average of 2.7, highlighting strong employee safety performance

AI summary of the CLX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $1,905M, up 33% YoY from $1,429M, driven by GOJO acquisition and lapping ERP-related shipment impacts
  • Gross margin 40.4% vs 41.7% YoY, down 130 basis points from higher commodity, manufacturing and logistics costs
  • Best segment: Health and Wellness sales up 55%, adjusted EBIT up 69%; worst: International sales up 11%, adjusted EBIT up 63%
  • Operating cash flow $143M vs $93M YoY; financing outflows $68M, with $1,175M debt primarily funding GOJO acquisition
  • Outlook: volatile, challenging environment; tariff, consumer spending, commodity and geopolitical headwinds, with continued brand investment and GOJO integration Candida

AI summary of the CLX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All 10 director nominees elected, with support ranging from 95.2% to 97.4% of votes cast
  • Executive compensation approved on an advisory basis, receiving 92.0% of votes cast
Filed Nov 2, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal Q1 2026 results for quarter ended September 30, 2026
  • Full financial results and management commentary in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Supplemental financial information for fiscal year 2026, provided in Exhibit 99.2
  • Exhibit may contain additional operating or financial metrics relevant to investor analysis

Item EX-99.1: Item EX-99.1

  • Q1 FY2027 net sales rose 33% to $1.91B, with GOJO contributing 15 points and ERP-transition comparisons contributing materially to organic growth
  • Adjusted EPS increased 82% to $1.55, while gross margin fell 130 basis points to 40.4% from higher commodity and logistics costs

Item EX-99.2: Item EX-99.2

  • Q1 FY2027 net sales $1.905B, up 33%, with 15% from GOJO acquisition and 18% organic growth
  • Health and Wellness led growth at 62%, including 39% acquisition impact and 23% organic growth
Filed Oct 29, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Fabian Garcia becomes CEO and director January 5, 2027, bringing Unilever, Revlon and Colgate-Palmolive leadership experience
  • Linda Rendle exits as CEO, Chair and director, remaining senior advisor through April 2, 2027 at $1,350,000 base salary

Item 7.01: Regulation FD Disclosure

  • CEO appointment: Mr. Garcia named chief executive officer effective October 29, 2026
  • Leadership transition creates potential strategic and execution changes for Clorox

Item EX-99.1: Item EX-99.1

  • Fabian Garcia appointed CEO effective January 5, 2027, succeeding Linda Rendle
  • Garcia joins Clorox’s board, while Matthew Shattock becomes independent chair

AI summaries of CLX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CLX

Don't miss the next CLX filing

  • Alerts as it files. A push when CLX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CLX, by share count.
  • Ask anything. An AI agent that reads every CLX filing and answers with sources.

CLX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Breber Pierre RBuyNov 4, 2026$100.06
Marriner KirstenFOct 5, 2026$80.41
Barton NinaFOct 5, 2026$80.41
Rendle Linda JAOct 5, 2026$80.41
Marriner KirstenAOct 5, 2026$80.41
Marriner KirstenFOct 5, 2026$80.41
Bellet LucFOct 5, 2026$80.41
Bellet LucAOct 5, 2026$80.41

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$7.1B$7.1B
Gross Profit$2.9B$3.0B$3.2B
Net Income-$280.0M$810.0M
Gross Margin-43.0%45.2%
Net Margin-3.9%11.4%
Balance Sheet
Total Assets$5.9B$5.8B$5.6B
Equity-$328.0M$321.0M
ROE-85.4%252.3%
Per Share
EPS$1.20$2.25$6.52
Cash Flow
Operating CF-$695.0M$981.0M
CapEx$228.0M$212.0M$220.0M

Source: XBRL data in Clorox (CLX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CLX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CLX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202645$4.50B
Q2 202647$5.40B
Q1 202648$5.59B
Q4 202546$5.57B
Q3 202547$6.88B
Q2 202547$6.51B
Q1 202546$5.69B
Q4 202444$5.67B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 370 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CLX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
4Nov 5, 2026--
10-QNov 2, 2026Analysis
8-KNov 2, 2026Analysis-
8-KOct 29, 2026Analysis-
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 7, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
10-KAug 7, 2026Analysis

Related Consumer Staples companies

All Consumer Staples →

CLX SEC filings: frequently asked questions

Are CLX insiders buying or selling?

In the last 90 days, Clorox (CLX) officers, directors and 10% owners reported 1 open-market purchase worth $400,251 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CLX stock?

As of September 30, 2026, the largest Clorox (CLX) holders among the 13F filers tracked by SignalX were BlackRock ($657.9 million), Vanguard Capital Management LLC ($642.2 million), State Street Corp ($625.7 million), Invesco Ltd ($509.9 million), Vanguard Portfolio Management LLC ($458.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CLX's revenue in fiscal year 2025?

For the fiscal year ended June 30, 2025 (FY2025), Clorox (CLX) reported revenue of $7.1 billion (up 0.2% from FY2024) and net income of $810.0 million. Diluted EPS was $6.52. The figures come from the XBRL data in the 10-K.

What did CLX report in its latest 8-K?

Clorox (CLX) filed an 8-K on November 19, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All 10 director nominees elected, with support ranging from 95.2% to 97.4% of votes cast.

What are the latest CLX SEC filings?

Clorox (CLX) filed its latest 10-K annual report on August 7, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on November 5, 2026.

What is CLX's SEC CIK number?

Clorox (CLX)'s SEC Central Index Key (CIK) is 21076. EDGAR lists every CLX filing under that number.

Ask anything about CLX

The research agent reads CLX's filings, financials, insider trades and 13F holders, then answers with sources.